These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2906154)

  • 1. Role of dopamine D-1 and D-2 receptor subtypes in mediating dopamine agonist effects on food consumption in rats.
    Martin-Iverson MT; Dourish CT
    Psychopharmacology (Berl); 1988; 96(3):370-4. PubMed ID: 2906154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term motor stimulant effects of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO), a dopamine D-2 receptor agonist: interactions with a dopamine D-1 receptor antagonist and agonist.
    Martin-Iverson MT; Iversen SD; Stahl SM
    Eur J Pharmacol; 1988 Apr; 149(1-2):25-31. PubMed ID: 2899515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of (+)-4-propyl-9-hydroxynaphthoxazine on midbrain dopamine neurons: an electrophysiological study.
    Kelland MD; Freeman AS; LeWitt PA; Chiodo LA
    J Pharmacol Exp Ther; 1990 Oct; 255(1):276-84. PubMed ID: 1976800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of the behavioral effects of the selective dopamine D2 agonist (+)-4-propyl-9-hydroxynaphthoxazine by dopamine antagonists in monkeys.
    Rosenzweig-Lipson S; Bergman J
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1039-46. PubMed ID: 8099614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine and neurochemical effects of (+)-PHNO, a dopamine D2 agonist.
    Gust CM; Hemrick-Luecke SK; Fuller RW
    J Neural Transm; 1989; 75(1):11-20. PubMed ID: 2563751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of the enantiomers of the dopamine agonist N-0437 on food consumption and yawning behaviour in rats.
    Timmerman W; Rusk IN; Tepper P; Horn AS; Cooper SJ
    Eur J Pharmacol; 1989 Dec; 174(1):107-14. PubMed ID: 2575532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO].
    Martin GE; Williams M; Pettibone DJ; Yarbrough GG; Clineschmidt BV; Jones JH
    J Pharmacol Exp Ther; 1984 Sep; 230(3):569-76. PubMed ID: 6433000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PHNO, a novel dopamine agonist, in animal models of parkinsonism.
    Koller W; Herbster G; Gordon J
    Mov Disord; 1987; 2(3):193-9. PubMed ID: 2904649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic behavioural effects of dopamine D1 and D2 receptor agonists are determined by circadian rhythms.
    Martin-Iverson MT; Yamada N
    Eur J Pharmacol; 1992 Apr; 215(1):119-25. PubMed ID: 1355440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulant-conditioned locomotion is not affected by blockade of D1 and/or D2 dopamine receptors during conditioning.
    Martin-Iverson MT; McManus DJ
    Brain Res; 1990 Jun; 521(1-2):175-84. PubMed ID: 2145055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential actions of dopamine receptor antagonism in rats upon food intake elicited by either mercaptoacetate or exposure to a palatable high-fat diet.
    Baker RW; Osman J; Bodnar RJ
    Pharmacol Biochem Behav; 2001; 69(1-2):201-8. PubMed ID: 11420087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-1 and D-2 receptor antagonists decrease corn oil sham feeding in rats.
    Weatherford SC; Smith GP; Melville LD
    Physiol Behav; 1988; 44(4-5):569-72. PubMed ID: 2907161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ageing on the behavioural responses to dopamine agonists: decreased yawning and locomotion, but increased stereotypy.
    Stoessl AJ; Martin-Iverson MT; Barth TM; Dourish CT; Iversen SD
    Brain Res; 1989 Aug; 495(1):20-30. PubMed ID: 2570627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs acting at D-1 and D-2 dopamine receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation.
    Collins P; Broekkamp CL; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1991; 103(4):503-12. PubMed ID: 1676528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic administration of a selective dopamine D-2 agonist: factors determining behavioral tolerance and sensitization.
    Martin-Iverson MT; Stahl SM; Iversen SD
    Psychopharmacology (Berl); 1988; 95(4):534-9. PubMed ID: 2905503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profile of the selective dopamine D-2 receptor agonist N-0437: its effects on palatability- and deprivation-induced feeding, and operant responding for food.
    Rusk IN; Cooper SJ
    Physiol Behav; 1988; 44(4-5):545-53. PubMed ID: 2976945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis.
    Imperato A; Di Chiara G
    Eur J Pharmacol; 1988 Nov; 156(3):385-93. PubMed ID: 2905668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic treatment with D1 and D2 dopamine receptor agonists: combined treatments interact to differentially affect brain levels of monoamines.
    Martin-Iverson MT
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Sep; 344(3):281-5. PubMed ID: 1683687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the involvement of dopamine D-1 and D-2 receptors in the anticonvulsant effect of dopamine agonists in various rodent models of epilepsy.
    Löscher W; Czuczwar SJ
    Eur J Pharmacol; 1986 Aug; 128(1-2):55-65. PubMed ID: 3758188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naltrexone, dopamine receptor agonists and antagonists, and food intake in rats: 1. Food deprivation.
    Hobbs DJ; Koch JE; Bodnar RJ
    Pharmacol Biochem Behav; 1994 Sep; 49(1):197-204. PubMed ID: 7816874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.